The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment

doi:10.3390/jcm10040707

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23513

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23513

Title:	The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment
Authors:	Huang, WC;Fu, PK;Chan, MC;Chin, CS;Huang, WN;Lai, KL;Wang, JL;Hung, WT;Wu, YD;Hsieh, CW;Wu, MF;Chen, YH;Hsu, JY
Keywords:	boost;long-term effectiveness;Omalizumab;real-world;severe allergic asthma
Date:	2021
Issue Date:	2022-08-05T09:38:30Z (UTC)
Publisher:	MDPI
Abstract:	The implications of boosting Omalizumab treatment (OT) in patients with severe allergic asthma (SAA) remain unclear. The study aimed to explore and compare the 12-month effectiveness between continuous, at least 10-month OT (continuation group) and four-month boost of Omalizumab (boost group) in adult patients with SAA. In this retrospective cohort study, clinical data were collected for further analysis. Of all participants (n = 124), a significant reduction in annual exacerbations (baseline = 0.8 +/- 1.5, follow-up = 0.5 +/- 1.0, p = 0.047 ) and improvement in small airway ventilation as evaluated by forced expiratory flow at 25-75% (baseline = 55.1 +/- 11.1%, follow-up = 59.4 +/- 8.4%, p < 0.001 ) were found in the continuation group (n = 110). By contrast, the boost group (n = 14) had significantly increased annual exacerbations (baseline = 0.7 +/- 1.4, follow-up = 2.9 +/- 3.6, p = 0.031 ) and impaired small airway function (baseline = 55.3 +/- 12.9, follow-up = 52.1 +/- 12.5, p = 0.026 ). Furthermore, the continuation group rather than the boost group had significant decreases in the frequency of oral corticosteroid (OCS) use as controllers (baseline = 32.7%, follow-up = 20.0%, p = 0.047 ; baseline = 50.0%, follow-up = 21.4%, p = 0.237, respectively) and OCS maintenance dose (mg/month) (baseline = 85.9 +/- 180.8, follow-up = 45.8 +/- 106.6, p = 0.020 ; baseline = 171.4 +/- 221.5, follow-up = 50.0 +/- 104.3, p = 0.064, respectively), and increases in asthma control test scores (baseline = 16.0 +/- 3.0, follow-up = 19.8 +/- 4.4, p < 0.001 *; baseline = 14.6 +/- 3.8, follow-up = 19.7 +/- 4.7, p = 0.050, respectively). Continuous OT would be beneficial for adult patients with SAA, while boost of Omalizumab would worsen their long-term outcomes.
URI:	http://dx.doi.org/10.3390/jcm10040707 https://www.webofscience.com/wos/woscc/full-record/WOS:000623983900001 https://ir.csmu.edu.tw:8080/handle/310902500/23513
Relation:	JOURNAL OF CLINICAL MEDICINE ,2021,v10,issue 4
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	175	View/Open

Loading...